Lonza’s Disinfectant Formulations Are Now EPA Approved To Combat Deadly Antibiotic-Resistant CRE Bacteria
Allendale, NJ, 23 April 2014 -- Lonza’s Hygiene & Preservation business is excited to announce its Lonzagard® R-82 family of disinfectants is now EPA approved to combat Carbapenem-Resistant Enterobacteriaceae (CREs). Untreatable and hard-to-treat infections from CRE bacteria are on the rise among patients in medical facilities. CRE have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection.
Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die as a direct result of these infections, according to the U.S. Centers for Disease Control and Prevention. The Lonzagard® R-82 family includes economical concentrates and convenient, ready-to-use disinfectants that are ideal for all types of healthcare facilities.
“Lonza aims to provide solutions that disinfect hard surfaces to kill CRE throughout healthcare facilities. Our highly effective disinfectants are a vital tool to kill disease-causing bacteria and viruses on hard surfaces that if left untreated can lead to the spread of hospital-acquired infections.” said Craig Carter, N.A. Marketing Manager for Lonza’s Hygiene business, which is a part of the company’s Consumer Care organization.
Lonza provides these and other technologies through partners who service the healthcare industry. Contact Lonza or your cleaning chemicals supplier today and ask about products powered by Lonzagard® technology.